WO2022218970A3 - Conjugués de pyrrolobenzodiazépine - Google Patents
Conjugués de pyrrolobenzodiazépine Download PDFInfo
- Publication number
- WO2022218970A3 WO2022218970A3 PCT/EP2022/059730 EP2022059730W WO2022218970A3 WO 2022218970 A3 WO2022218970 A3 WO 2022218970A3 EP 2022059730 W EP2022059730 W EP 2022059730W WO 2022218970 A3 WO2022218970 A3 WO 2022218970A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyrrolobenzodiazepine conjugates
- pyrrolobenzodiazepine
- conjugates
- formula
- unit
- Prior art date
Links
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne un conjugué de formule (I) : L - (DL)p, L étant une unité ligand (c'est-à-dire un agent de ciblage), p valant de 1 à 20, DL étant une unité de liaison de médicament de formule (I'); RLL étant un lieur pour la liaison à l'unité de ligand, D représentant D1; D' représentant D'1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2105187.5A GB202105187D0 (en) | 2021-04-12 | 2021-04-12 | Pyrrolobenzodiazepine conjugates |
GB2105187.5 | 2021-04-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022218970A2 WO2022218970A2 (fr) | 2022-10-20 |
WO2022218970A3 true WO2022218970A3 (fr) | 2022-12-29 |
Family
ID=75949628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/059730 WO2022218970A2 (fr) | 2021-04-12 | 2022-04-12 | Conjugués de pyrrolobenzodiazépine |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB202105187D0 (fr) |
WO (1) | WO2022218970A2 (fr) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013177481A1 (fr) * | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazépines et leurs conjugués |
WO2014057074A1 (fr) * | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazépines et leurs conjugués |
WO2020079229A1 (fr) * | 2018-10-19 | 2020-04-23 | Medimmune Limited | Conjugués de pyrrolobenzodiazépine |
WO2020205564A1 (fr) * | 2019-03-29 | 2020-10-08 | Immunogen, Inc. | Dérivés de bis-benzodiazépine cytotoxiques et leurs conjugués avec des agents de liaison à une cellule pour inhiber la croissance cellulaire anormale ou pour traiter des maladies prolifératives |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58180487A (ja) | 1982-04-16 | 1983-10-21 | Kyowa Hakko Kogyo Co Ltd | 抗生物質dc−81およびその製造法 |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
PL2270010T3 (pl) | 2004-03-01 | 2012-07-31 | Medimmune Ltd | Pochodne 11-hydroksy-5h-pirolo[2,1-c][1,4]benzodiazepin-5-onu jako kluczowe związki pośrednie do otrzymywania c2 podstawionych pirolobenzodiazepin |
BRPI0516284A (pt) | 2004-09-23 | 2008-09-02 | Genentech Inc | anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto |
NZ563136A (en) | 2005-04-21 | 2009-11-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
RS52060B (en) | 2006-01-25 | 2012-04-30 | Sanofi | CYTOTOXIC AGENTS CONTAINING NEW TOMAIMYCIN DERIVATIVES |
JP5290276B2 (ja) | 2007-05-08 | 2013-09-18 | ジェネンテック, インコーポレイテッド | システイン改変抗muc16抗体および抗体−薬物結合体 |
WO2009052249A1 (fr) | 2007-10-19 | 2009-04-23 | Genentech, Inc. | Anticorps anti-tenb2 modifiés par des cystéines et conjugués anticorps-médicament |
EA024730B1 (ru) | 2010-04-15 | 2016-10-31 | Медимьюн Лимитед | Пирролбензодиазепиновые соединения, их конъюгаты, фармацевтические композиции, содержащие указанные конъюгаты, и применение указанных конъюгатов |
FR2967466B1 (fr) | 2010-11-16 | 2014-10-24 | Renault Sa | Procede de detection des defauts de combustion d'un moteur a combustion interne |
GB201106173D0 (en) | 2011-04-12 | 2011-05-25 | Adc Biotechnology Ltd | System for purifyng, producing and storing biomolecules |
EA031585B1 (ru) | 2012-12-21 | 2019-01-31 | Медимьюн Лимитед | Пирролобензодиазепины и их конъюгаты |
CN106459205B (zh) | 2014-04-11 | 2021-04-09 | 免疫医疗有限责任公司 | 包含半胱氨酸工程化抗体的轭合化合物 |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
KR20190083654A (ko) | 2016-11-10 | 2019-07-12 | 메디뮨 엘엘씨 | Asct2에 특이적인 결합 분자 및 이의 용도 |
CN112203696A (zh) | 2018-05-25 | 2021-01-08 | 免疫医疗有限公司 | 吡咯并苯并二氮杂*缀合物 |
-
2021
- 2021-04-12 GB GBGB2105187.5A patent/GB202105187D0/en not_active Ceased
-
2022
- 2022-04-12 WO PCT/EP2022/059730 patent/WO2022218970A2/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013177481A1 (fr) * | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazépines et leurs conjugués |
WO2014057074A1 (fr) * | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazépines et leurs conjugués |
WO2020079229A1 (fr) * | 2018-10-19 | 2020-04-23 | Medimmune Limited | Conjugués de pyrrolobenzodiazépine |
WO2020205564A1 (fr) * | 2019-03-29 | 2020-10-08 | Immunogen, Inc. | Dérivés de bis-benzodiazépine cytotoxiques et leurs conjugués avec des agents de liaison à une cellule pour inhiber la croissance cellulaire anormale ou pour traiter des maladies prolifératives |
Non-Patent Citations (4)
Title |
---|
BREANNA S. VOLLMAR ET AL: "Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual [beta]-glucuronide and dipeptide triggers", BIOCONJUGATE CHEMISTRY, vol. 28, no. 10, 22 September 2017 (2017-09-22), pages 2538 - 2548, XP055551756, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.7b00365 * |
GREGSON STEPHEN J ET AL: "Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual [beta]-glucuronide and dipeptide triggers", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 179, 18 June 2019 (2019-06-18), pages 591 - 607, XP085772542, ISSN: 0223-5234, [retrieved on 20190618], DOI: 10.1016/J.EJMECH.2019.06.044 * |
KATIE E. ARCHER ET AL: "Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody-Drug Conjugates (ADCs)", ACS MEDICINAL CHEMISTRY LETTERS, vol. 10, no. 8, 22 July 2019 (2019-07-22), pages 1211 - 1215, XP055705444, ISSN: 1948-5875, DOI: 10.1021/acsmedchemlett.9b00254 * |
NAZZARENO DIMASI ET AL: "Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion", MOLECULAR PHARMACEUTICS, vol. 14, no. 5, 16 March 2017 (2017-03-16), pages 1501 - 1516, XP055417109, ISSN: 1543-8384, DOI: 10.1021/acs.molpharmaceut.6b00995 * |
Also Published As
Publication number | Publication date |
---|---|
WO2022218970A2 (fr) | 2022-10-20 |
GB202105187D0 (en) | 2021-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY197127A (en) | Pyrrolobenzodiazepine conjugates | |
WO2007064345A3 (fr) | Composés de bis-1,8-naphtalimide substitués par un groupe hétérocyclique, conjugués anticorps-médicament et procédés d'utilisation de ceux-ci | |
AU3000800A (en) | Phosphocholine linked prodrug derivatives | |
MX2013014583A (es) | Conjugados de proteina-polimero-farmaco. | |
CU23105A3 (es) | DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS | |
TW200500069A (en) | Vitamin-receptor binding drug delivery conjugates | |
JO2744B1 (en) | Cytotoxic agents, including new tomaymycin derivatives and their therapeutic use | |
NZ597964A (en) | Long acting insulin composition | |
MX2018009585A (es) | Conjugados de pirrolobenzodiazepina. | |
MA28653B1 (fr) | Nouveaux derives fluoroglycosidiques des pyrazoles, les medicaments contenant ces composes et leur utilisation | |
EA200800657A1 (ru) | Способ приготовления очищенных конъюгатов лекарственных средств | |
TW200637869A (en) | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same | |
GB0220198D0 (en) | Modified saccharides,conjugates thereof and their manufacture | |
MA34469B1 (fr) | Dérivés anticancéreux, préparation de ceux-ci et utilisation thérapeutique de ceux-ci | |
WO2008076333A8 (fr) | Polymères à base de cyclodextrine pour administration d'agents thérapeutiques | |
WO2011010084A8 (fr) | Conjugués de cyclosporine | |
WO2007106544A3 (fr) | Conjugues de chelation presentant une fraction aromatique substituee et leurs derives | |
MX2010005813A (es) | Conjugados oligomero-triciclicos. | |
Ghosh et al. | Chemical and biological explorations of the family of CC-1065 and the duocarmycin natural products | |
MX2023001648A (es) | Conjugado de anticuerpo y farmaco. | |
AU2003250391A1 (en) | Conjugates of biocompatible polymers with nuclide activation therapy reagents | |
MD3870234T2 (ro) | Conjugate anticorp-medicament care conțin derivați de ecteinascidină | |
AU2002215904A1 (en) | Compounds with a branched linker | |
WO2006105201A3 (fr) | Conjugues constitues d'acide gras et de peptide derive du gp41 du vih | |
WO2022218970A3 (fr) | Conjugués de pyrrolobenzodiazépine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22722261 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22722261 Country of ref document: EP Kind code of ref document: A2 |